From PhRMA

Legislators continued to push harmful price-setting policies this year that could increase costs and reduce access to medications for millions of seniors who rely on Medicare. We’re already seeing these policies threaten research and development for critical treatments for conditions like diabetes, autoimmune diseases and blood cancers.

Looking ahead: If action isn’t taken, 3.5 million Part D patients could see higher out-of-pocket costs by 2026. We look forward to collaborating with legislators to ensure patients can access the medicines they need.

Year after year, the federal 340B hospital markup program continues to grow, but patients aren’t benefitting. Originally designed to help vulnerable patients and communities, the program has since become a hospital profit stream. This is increasing costs for everyone else, particularly patients, employers and taxpayers.

Looking ahead: As seen in Michigan and Minnesota, many across the country realize 340B isn’t benefiting patients as intended. We will continue to advocate for an effective and patient-focused 340B program.